INTRODUCTION:

Winston Churchill, the highly aphoristic and epigrammatic Prime Minister of Great Britain from 1941 to 1945. Not even the start of the end, exactly. However, it may mark the a decision of the beginning. The introduction and some of the middle chapters of the SARS-CoV-2 pandemic, which marks the end of the starting but also, possibly, the beginning of the end as the containment and mitigation measures to limit the spread of the disease finally begin to take effect, are the only parts of the story that have been written¹. The presumption is that COVID-19 comes to an end when symptoms go away and no one dies.

So, early detection and treatment are given the most attention (appropriately). Antivirals, immune modulators, and cytokine-targeted medicines are the mainstays of therapeutic therapy, with the goal of resuscitating patients as soon as possible and calming the "cytokine storm"²that leads to multiple organ failure disorder (MODS). On the bases of Clinical symptoms on patients are the tip of the metaphorical COVID-19 iceberg, but early anecdotal evidence of post-COVID morbidity³and mortality⁴the submerged portion of the iceberg, suggests an urgent need for and focus on specialized aftercare, particularly as a wave of patients are declared "recovered" and discharge from ICUS. We have developed the umbrella term "persistent post-COVID syndrome" (PPCS) to describe these effects, drawing comparisons with post-sepsis syndrome⁵and post-ICU syndrome⁶emerging pathological entities characterized by a clinically significant decline in quality of life (QOL) and an increased risk of indolent death associated with a constellation of effects that persist long after the resolution of infectious symptoms. The dismal course of COVID survivors post-ICU. Additionally, by comparison with post-sepsis syndrome, which affects 50% of sepsis survivors and has been called a "hidden public health disaster⁷, these long-term PPCS effects may be so severe as to exceed current medical infrastructure. The appropriate management and prevention of potential long-term PPCS sequelae have received relatively little attention, despite several strategies to optimize management of the acute COVID-19 episode being evaluated. This may be due to the remoteness of symptoms from the incident infection and/or the current emphasis on "one clinical catastrophe at a time" and "first things first." Overexpression of transforming growth factor, which is discussed in more detail below, may serve as a unifying theory to explain chronic illness. This articles represent address (1) a possibles TGF driven mechanism of persistent post COVID-19 syndrome, (2) a summary of clinical methods of PPCS, and (3) methods of diagnosis and treatment of PPCS.

MECHANISM OF COVID-19:

· An difficult and lengthy opposite recompensed anti-inflammatory response syndrome (CARS) follows trauma or a severe primary infectious disease like COVID-19, in which a systemic inflammatory response syndrome (SIRS) or SIRS is dominates, and this results in postinfectious/posttraumatic immunosuppression⁸. The CARS response, a mirror-imaged counter-regulation to SIRS or systemic inflammatory response syndrome, has the role of reducing the proinflammatory state and preventing excessive multiple-organ failure⁹. And control the restoration of immunologic normality or homeostasis¹⁰.

· The final outcome in COVID-19 is ultimately determined by a delicate balance of pro- and anti-inflammatory responses, i.e., SIRS and CARS, which is orchestrated by a number of concurrently interacting and antagonistic components¹¹. The presence or absence of comorbidities, viral exposure or inoculum, and immunocompetence are all factors that can cause excessive inflammatory reactions¹². These reactions are characterized by an excessive release of inflammatory cytokines like interleukins 1, 6, 8, 17, and 1, monocyte chemoattractant protein-1, and tissue. Acute lung injury (ALI), acute respiratory distress syndrome (ARDS), coagulopathy, hypotension, hypoperfusion, organ failure (also known as multiple-organ failure (MOF) or multiple-organ dysfunction syndrome (MODS), and death result from this process if it continues unabatedly¹³.

· On the other hand, if the inflammatory response is suppressed too much in the direction of CARS, the patient may enter a stage of protracted immunosuppression known as PICS for persistent inflammation¹⁴immunosuppression, and catabolism syndrome after managing to "weather" the initial hyperinflammatory cytokine storm and the progression to ARDS. PICS is a condition seen after sepsis and is one of the hypothesized causes of persistent ST-COVID syndrome (PPCS)¹⁵,

· This idea is supported by the fact that post-septic patients are risk to latent virus reactivation¹⁶ and that SARS-CoV-2 has been recover or reactivated in COVID-19 patients who have recovered^16,17. The likelihood of after that bacterial and fungal infections in COVID-19 patients¹⁸ is the same as that in sepsis¹⁹, showing the immunological imbalanced and suppression.

· In addition to losing immunological ability, post-COVID patients are also at risk for developing pulmonary fibrosis, which is distinct from interstitial pulmonary fibrosis (IPF) and is frequently observed in follow-up imaging of recovered patients²⁰. Since the related symptoms of dyspnea, fatigue, and weakness appear to be out of proportion to the level of ongoing lung damage and the severity of gas exchange impairment, it is difficult to determine the exact extent to which post-ARDS fibrosis constitutes an issue²¹.

· Transforming growth factor beta (TGF-B) is a multifunctional cytokine that is raised during and after sepsis as well as during and after COVID-19²¹, probably to balance out the immunosuppressive, profibrogenic, and anti-inflammatory actions.

· TGF-B participation is suggested by histologic alterations in the lungs of COVID-19 patients²², which show interstitial fibrosis and fibroblastic proliferations²³. TGF- signaling, which is regulated by Smad proteins or MAP kinases and Akt²⁴, thus potentially represents an alluring target for therapeutic intervention as a potent inducer of fibrosis and immunosuppression.

Pulmonary Fibrosis and Dysfunction:

· While the majority of COVID-19 infection are mild, 5-8% of infection individuals adult respiratory distress syndrome, or ARDS, which is defined by hypoxemia, bilateral lung infiltrates and coughing up blood, often requiring mechanical ventilation^26,27.

· Exudative, proliferative, and fibrotic phases are has been suggested to be present in the pathologic progression of ARDS²⁸. Alveolar flooding and respiratory distress result from the exudative phase's production of proinflammatory cytokines like IL-1, TNF, and IL-6, neutrophil influx, and breakdown of the endothelial- epithelial barrier²⁹.The fibroproliferative phase, which comes after the exudative phase and is well defined by the an buildup of fibrocytes, fibroblasts, and myofibroblasts in the alveolar compartment, causes an excessive deposition of matrix substances such fibronectin, collagen I, and collagen III.

· Mechanical ventilation is one of the factors that causes an ARDS fibroproliferative response because shear forces also promote collagen synthesis and prevent collagenase production in addition to secreting transforming growth factor.³⁰

Only a few percent of ARDS survivors and, by consequently, COVID-19 patients, progress to pulmonary fibrosis.

· This condition is well defined by exercise-induced breathlessness and a chronic dry cought³¹. Its management consists primarily of supportive measures like extra oxygen, pulmonary rehabilitation, and vaccination against influenza and streptococcus pneumoniae³². Though they are not curative, nintedanib, and pirfenidone, two FDA-approved drugs, have been shown to slow the development of pulmonary fibrosis³³. For up to 5 years following ARDS, these patients, whose mortality risk is increased, may still present with activity limits and a poorer quality of life³⁴.

Cardiac Fibrosis and Dysfunction:

Patients with COVID-19 frequently exhibit myocardial damage symptoms, such as heart failure and myocarditis, as well as an increase of already present cardiovascular illness, as indicated by raised troponin T (T n T) and brain natriuretic peptide (BNP) levels³⁵. The following are examples of injury-causing mechanisms:

· Right heart failure and pulmonary hypertension as a result of increased pulmonary vascular resistance.

· Renin-angiotensin system (RAS) overstimulation. This mediates harmful effects on the cardiovascular system, such as secondary hyperaldosteronism, hypokalemia, and cardiac arrhythmias³⁶.

· Pro-inflammatory cytokines cause the breakdown of plaque of the artery walls inflammatory cytokines can cause injury, particularly when there are already present coronary artery disorders³⁷.

· Viral infection of heart cell via ACE-2 resulting in myocarditis.

· Due to an imbalance between myocardial oxygen supply and demand brought on by ARDS's severe hypoxemia and reduced venous return, myocardial ischemia and necrosis occurs. Possible anti-COVID drugs, such as the macrolide antibiotic azithromycin, have been linked to cardiotoxicity and a prolonged QT interval³⁸.

· Tocilizumab, which raises cholesterol levels³⁹, chloroquine/hydroxychloroquine, which may cause conduction defects in the heart, and lopinavir/ritonavir, protease inhibitors that may lengthen PR and QT intervals and also inhibit CYP3A4 activity, which affects how other cardiac drugs, such as statins, are metabolized^40..

· The left ventricle wall's swelling and fibrosis, which result in decreased contractility and difficult overall function, are the characteristics of myocardial damage⁴¹and TGF-, the principal profibrotic cytokine, plays a important role in this modification process. Given the genetic similarity between SARS-CoV-1 and SARS-CoV-2, extrapolation from SARS-CoV-1 patients, who after 12-years of follow-up exhibited cardiovascular problems in 40%⁴² may be possible to predict long-term cardiac effects of COVID-19.

Neurological Fibrosis and Dysfunction:

· The respiratory symptoms of SARS-CoV-2 infection usually include fever, coughing, dyspnea, and sore throats, but they can also include anosmia and dysgeusia^43. which may show that the virus is neurotropic. An increased rate of neurologic symptoms was observed in a previous case study of 214 patients in Wuhan, China. 78 (36.4%) patients exhibited symptoms involving the central nervous system (CNS), the peripheral nervous system (PNS), or the skeletal muscles⁴⁴. Headache (13.1%) and dizziness (16.8%) were the two most prevalent CNS symptoms. Ataxia, seizures, acute cerebrovascular illness, and diminished awareness were also recorded.

· With the exception of the brain, where fibrogenic cells are confined to specific niches, tissue fibrosis is a frequent reaction to injury in the majority of body organs⁴⁵. However, scar formation is generated when the blood-brain barrier is disrupted, for example, by a cytokine storm or by a virus that directly injures neural tissue.

· In sepsis survivors, neurologic and psychological consequences are frequently observed^46,47. After SARS-CoV-2 infection, neuropsychiatric symptoms have also been documented⁴⁸. Depression, anxiety, and psychosis are some of these symptoms⁴⁹.

· Since there are numerous neurological conditions such as mental illness, anxiety, depression, and amyotrophic lateral sclerosis (ALS), as well as AIDS dementia complex, Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. The dysregulation of TGF-B signaling is related to. This cytokine is an achievable therapeutic target for the neurological and mental effects of COVID-19.

Management:

· Depending on the symptom profile and treatment requirements of each every patient, management methods for the treatment of post-COVID symptoms will vary extensively. Prior previous medical issues should be taken into account in management plans, and care teams should follow up with each patient on a regular basis until symptoms go away and for a while after that.

· A structure of general guidelines for the management of patients with possibles or confirmed PPCS is described in Table 2. In the following, we analyze potential therapeutic solutions for particular post-COVID symptoms

· Due to the complex temporal fluctuations of pro- and anti-inflammatory cytokines in sepsis, immuno modulatory therapies (e.g., GM-CSF, pooled intravenous immunoglobulins (IVIG), , interleukin-7, PD-L1 inhibitors, and IL-3) are likely warranted in order to prevent or reverse the anti-inflammatory phenotype.

· However, ongoing swelling, immunosuppression, and catabolism, also known as PICS, dominate in post-sepsis disorder resulting in PPCS. This is why it is important to research immunomodulatory therapies like immune checkpoint inhibitors, TGF- inhibitors, hematopoietic growth factors, cytokines, and others.

· TEW-7197, a brand-new small-molecule inhibitor, ALK5 inhibitor that prevents TGF-1-induced Smad/ TGFß, a drug called fresolimumab (GC1008, Genzyme/Sanofi) that signals, Pan-TGF- blocking completely human monoclonal antibody, Tasisulam (LY573636), (TGF-B1, (TGF-B2, and (TGF-B3)), BETA PRIME, a small-molecule TGF- inhibitor, Adapat-001.

Guidelines for the management of patient with suspected or confirmed PPCS

1.	The patient is examined by doctor who maps out any present symptoms or health issues.
2.	Determine COVID-19 exposure status, probable disease histories, and clinical testing options by oral history.
3	Cheak for any chronic medical illness or co-morbidities that may not be COVID-19
4.	Provide proper medical care for underlying chronic disease or established acute symptoms.
5.	Inform the patient of any potentials long term COVID-19 sequelae, commonly known as PPCS symptoms.
6.	Keep up with routine patient follow up encourage the patient to get help when their symptoms starts to get worse.

CONCLUSION:

· The temporal difference between acute and persistent symptoms

· A lack of understanding of post-COVID and post-ICU pathology, which may prevent "connecting the dots" between the multi-system indications and symptoms.

· The problem of whether and how much a severe sickness is to blame for and how to solve it

· Whether previous comorbidities and pre-COVID clinical histories influence the post-COVID burden and are to blame for pushing frail patients with low resistance past a point of no return, or whether and to what extent they are directly related to prolonged post-COVID disease. Last but not least, it is unsure that there will ever be a "magic bullet" treatment for PPCS that will completely "roll back" the symptoms; however, given that the main problems with PPCS may include immune paresis which leads to susceptibility to secondary infections as well as fibrotic remodeling in the lungs, heart, and brain that arises as a result of a chronic inflammatory process^50.

REFERENCES:

1. Milne GJ, Xie S. The efectiveness of social distancing in mitigating COVID-19 spread: a modelling analysis. medRxiv. 2020. 03.20.20040055

2. Misra DP, Agarwal V, Gasparyan AY et al. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020

3. https://nypost.com/2020/03/13/coronavirus-survivors-may-suferfrom-reduced-lung-function/

4. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (2020) Real estimates of mortality following COVID-19 infection [published online ahead of print, 2020 Mar 12]. Lancet Infect Dis S1473–3099(20)30195-X

5. Mostel Z, Perl A, Marck M et al. Post-sepsis syndrome - an evolving entity that aficts survivors of sepsis. Mol Med.2019; 26(1).

6. Stam HJ, Stucki G, Bickenbach J. Covid-19 and post intensive care syndrome: a call for action. J Rehabil Med. 2020; 52(4): jrm00044 7.

7. Angus DC. The lingering consequences of sepsis: a hidden. 2010

8. Angus DC. The lingering consequences of sepsis: a hidden public health disaster? JAMA. 2010; 304(16): 1833-4

9. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13:862–874

10. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996; 24:1125–1128

11. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of infammation: what controls its onset?. Front Immunol. 2016; 7:160.

12. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT. Cytokine profles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007; 11(2): R49

13. Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016; 274(1): 330–353

14. Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic infammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fbrin?. Semin Thromb Hemost. 2018; 44(3): 224–238

15. Biradar V, Moran JL (2011) SIRS, Sepsis and Multiorgan Failure. In: Fitridge R, Thompson M, editors. Mechanisms of vascular disease: a reference book for vascular specialists [Internet]. Adelaide (AU): University of Adelaide Press 17. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534275/

16. Hamers L, Kox M, Pickkers P () Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. 2015; 81(4): 426-39.

17. Walton AH, Muenzer JT, Rasche D et al. Reactivation of multiple viruses in patients with sepsis. PLoS One. 2014; 9(2): e98819.

18. https://www.npr.org/secti ons/coronaviru s-live-updat es/ 2020/04/17/836747242/in-south-korea-a-growing-number-ofcovid-19-patients-test-positive-after-recover

19. https://www.reuters.com/article/us-health-coronavirus-southkorea/ south-korea-reports-more-recovered-coronavirus-patients-testingpositive-again-idUSKCN21V0JQ

20. Xu K1, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J et al. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience].[Article in Chinese] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(1):0

21. Shi H, Han X, Jiang N et al. Radiological fndings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20(4): 425–434

22. Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons from Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. AJR Am J Roentgenol. 2020: 1-5

23. Russell B, Moss C, George G et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancer Med Sci. 2020; 14:1022.

24. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020; 20: 30132–5

25. Russell B, Moss C, George G et al. Associations between immune-suppressive and stimulating drugs and novel COVID19-a systematic review of current evidence. Ecancer Med Sci. 2020; 14: 1022.

26. NIHR (2020) Living with covid-19. A dynamic review of the evidence around ongoingcovid-19 symptoms (often called long covid). https:// evidence.nihr.ac.uk/themedreview/living-with-covid19

27. https://www.uptodate.com/contents/coronavirus-disease-2019- covid-19-critical-care-issues

28. Matuschak GM, Lechner AJ. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med. 2010; 107(4): 252–258

29. Walkey AJ, Summer R, Ho V, Alkana P. Acute respiratory distress syndrome: epidemiology and management approaches. Clin Epidemiol. 2012; 4:159–169

30. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS?. Am J Physiol Lung Cell Mol Physiol. 2014; 306(3): L217–L230

31. Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP. The fbroproliferative response in acute respiratory distress syndrome: mechanisms and clinical signifcance. Eur Respir J. 2014; 43(1): 276–285

32. Kouzbari K, Hossan MR, Arrizabalaga JH et al. Oscillatory shear potentiates latent TGF-β1 activation more than steady shear as demonstrated by a novel force generator. Sci Rep. 2019; 9: 6065

33. Johannson K, Collard HR. Acute exacerbation of idiopathic pulmonary fbrosis: a proposal. Curr Respir Care Rep. 2013; 2(4): https:// doi.org/10.1007/s13665-013-0065-x

34. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. ATS/ ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An ofcial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fbrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788

35. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011; 364(14):1293–1304

36. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020; 14(3): 247–250

37. Vaidya A, Dluhy R. (2000) Hyperaldosteronism. [Updated 2016 Oct 19]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK279065/

38. Young BE, Ong SWX, Kalimuddin S et al (2020) Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA ([Internet]. Available from:): 1–7

39. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis

40. Soubrier M, Pei J, Durand F, Gullestad L, John A. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther. 2017; 4(1):133-149

41. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart. Int J Cardiol. 2020; S0167–5273(20)31593-X

42. Biernacka A, Frangogiannis NG. Aging and Cardiac Fibrosis. Aging Dis. 2011; 2(2):158–173

43. Wu Q, Zhou L, Sun X. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep . 2017; 7:9110

44. Giacomelli A, Pezzati L, Conti F et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a crosssectional study. Clin Infect Dis. 2020.

45. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic Clinical Reviews in Allergy & Immunology 1 3 Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol

46. Fernández-Klett F, Priller J. The fibrotic scar in neurological disorders. Brain Pathol. 2014; 24(4):404-13

47. Gawlytta R, Niemeyer H, Böttche M, Scherag A, Knaevelsrud C, Rosendahl J. Internet-based cognitive-behavioural writing therapy for reducing post-traumatic stress after intensive care for sepsis in patients and their spouses (REPAIR): study protocol for a randomised-controlled trial. BMJ Open. 2017; 7(2): e014363

48. Annane D, Sharshar T. Cognitive decline after sepsis. Lancet Respir Med. 2015; 3(1):61–9

49. Wu, Yeshun, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain. Behav. Immun. 2020. https://| doi.org/10.1016/j.bbi.2020.03.031

50. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms [published online ahead of print, 2020 Apr 13]. Brain Behav Immun. 2020; S0889–1591(20)30489-X

51. Kashima R, Akiko Hata A. The role of TGF-β superfamily signaling in neurological disorders. Acta Biochimica et Biophysica Sinica. 2018; 50(1):106–120

Received on 06.11.2023 Modified on 02.12.2023

Asian J. Pharm. Tech. 2024; 14(1):73-78.

DOI: 10.52711/2231-5713.2024.00014